Cannabinoid CB1 and CB2 receptors antagonists AM251 and AM630 differentially modulate the chronotropic and inotropic effects of isoprenaline in isolated rat atria.

Abstract

Drugs targeting CB1 and CB2 receptors have been suggested to possess therapeutic benefit in cardiovascular disorders associated with elevated sympathetic tone. Limited data suggest cannabinoid ligands interact with postsynaptic β-adrenoceptors. The aim of this study was to examine the effects of CB1 and CB2 antagonists, AM251 and AM630, respectively, at functional cardiac β-adrenoceptors. Experiments were carried out in isolated spontaneously beating right atria and paced left atria where inotropic and chronotropic increases were induced by isoprenaline and selective agonists of β1 and β2-adrenergic receptors. We found four different effects of AM251 and AM630 on the cardiostimulatory action of isoprenaline: (1) both CB receptor antagonists 1 μM enhanced the isoprenaline-induced increase in atrial rate, and AM630 1 μM enhanced the inotropic effect of isoprenaline; (2) AM251 1 μM decreased the efficacy of the inotropic effect of isoprenaline; (3) AM251 0.1 and 3 μM and AM630 3 μM reduced the isoprenaline-induced increases in atrial rate; (4) AM630 0.1 and 3 μM enhanced the inotropic effect of isoprenaline, which was not changed by the same concentrations of AM251. Our results show that the CB1 and CB2 receptor antagonists AM251 and AM630 have bidirectional effects on the cardiostimulatory action of isoprenaline, most likely related to an interaction with β1-adrenoceptors. Provided that the results translate to human heart, caution should be taken when using CB1 and CB2 receptor antagonists, as an enhanced sympathetic tone accompanies many cardiovascular disorders.